Last reviewed · How we verify
Hib-MenC-TT
Hib-MenC-TT is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Haemophilus influenzae type b disease, Neisseria meningitidis serogroup C disease, Neisseria meningitidis serogroup Y disease. Also known as: MenC-TT.
Conjugate vaccine that induces immunity against Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y
Hib-MenC-TT is a vaccine that has been studied for its effectiveness against Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease, Diphtheria, Tetanus, Pertussis, and Hepatitis B. It is a small molecule vaccine, classified as a 6-in-1 vaccine that includes protection against Hib.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hib-MenC-TT |
|---|---|
| Also known as | MenC-TT |
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
Hib-MenC-TT is a conjugate vaccine that combines the Hib capsular polysaccharide with the outer membrane protein complex of Neisseria meningitidis serogroups C and Y, and the tetanus toxoid protein. This combination induces immunity against Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y.
Approved indications
- Haemophilus influenzae type b disease
- Neisseria meningitidis serogroup C disease
- Neisseria meningitidis serogroup Y disease
Common side effects
Key clinical trials
- Hepatitis B Vaccination in Infants (PHASE4)
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (PHASE2)
- Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old (PHASE2)
- Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (PHASE2)
- Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib-MenC-TT CI brief — competitive landscape report
- Hib-MenC-TT updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Hib-MenC-TT
What is Hib-MenC-TT?
How does Hib-MenC-TT work?
What is Hib-MenC-TT used for?
Who makes Hib-MenC-TT?
Is Hib-MenC-TT also known as anything else?
What drug class is Hib-MenC-TT in?
What development phase is Hib-MenC-TT in?
Related
- Drug class: All Conjugate vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Vaccines
- Indication: Drugs for Haemophilus influenzae type b disease
- Indication: Drugs for Neisseria meningitidis serogroup C disease
- Indication: Drugs for Neisseria meningitidis serogroup Y disease
- Also known as: MenC-TT
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing